Back to home » Treatment News
 August 30, 2006
|
Liver Disease Is Leading Cause of Death
In the United States,
Europe and Australia, the leading cause of non-AIDS mortality is
liver-related, a European consortium reports in the Archives of
Internal Medicine.
|
|
|
Colonic Neoplasms Prevalent in People With HIV
Colonic neoplasms detected
by flexible sigmoidoscopy are more prevalent in HIV-infected patients
than in the general population, report New York City-based clinicians
in the August 14/28 issue of the Archives of Internal Medicine.
|
|
|
| August 29, 2006
|
| August 24, 2006
|
August 22, 2006
|
IAC: Is Kaletra Monotherapy Possible?
Ten years after combination HIV treatment was heralded as the one and only way to treat HIV, data are emerging to suggest that monotherapy—the use of just one HIV drug—may, in fact, be a possibility.
|
|
|
Prostatectomy Safe When HIV Is Asymptomatic
Radical prostatectomy can be safe and effective in selected HIV-positive patients who are asymptomatic, have higher CD4+ cell counts, and have albumin levels in the normal range.
|
|
|
August 21, 2006
|
IAC: Sustiva vs. Kaletra? We Have a Likely Winner
The U.S. Department of Health and Human Services (DHHS) currently recommends either Sustiva® (efavirenz) or Kaletra® (lopinavir plus ritonavir) — in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) — for HIV-positive people starting treatment for the first time.
|
|
|
August 18, 2006
|
IAC: Markowitz on MK-0518
AIDSmeds Founder Peter Staley interviewed Dr. Martin Markowitz of the Aaron Diamond AIDS Research Center and one of the investigators who announced very promising results about MK-0518.
|
|
|
August 17, 2006
|
IAC: Lexiva Measures Up to Kaletra
Final data from a 48-week study comparing Norvir® (ritonavir)-boosted Lexiva® (fosamprenavir) to Kaletra® (ritonavir-boosted lopinavir) reported today at the XVI International AIDS Conference (IAC) in Toronto indicate that these two protease inhibitor (PI) options have comparable safety and effectiveness.
|
|
|
IAC: Maraviroc Less Effective but Safe for Some
Results from a clinical trial presented at the XVI International AIDS Conference (IAC) indicate that maraviroc, Pfizer's experimental entry inhibitor, may be of limited benefit in HIV-positive people with a specific form of HIV.
|
|
|
IAC: Vicriviroc Shows Promise
The AIDS Clinical Trials Group has reported results from a clinical trial of vicriviroc, an experimental entry inhibitor being developed by Schering-Plough.
|
|
|
IAC: Data, Access for Integrase Inhibitor
Preliminary results from an ongoing clinical trial of MK-0518, Merck's experimental integrase inhibitor, suggest that it has comparable anti-HIV activity to Sustiva® (efavirenz) after 24 weeks of treatment.
|
|
|
IAC: Encouraging TNX-355 Data
Forty-eight week results from a phase II clinical trial of TNX-355, an HIV-entry inhibitor, were reported today at the XVI International AIDS Conference in Toronto.
|
|
|
IAC: Growth Hormone for Lipo
Following on the heels of a published clinical trial showing that recombinant human growth hormone (rhGH) treatment is associated with reductions in unhealthy fat seen in HIV-positive people with lipodystrophy, encouraging results from a second study were reported today at the XVI International AIDS Conference (IAC) in Toronto.
|
|
|
IAC: Kotler Responds to Critics of FRAM
AIDSmeds Founder Peter Staley interviewed Dr. Donald Kotler, Chief of Gastroenterology at St. Luke's-Roosevelt Hospital and one of the investigators in the controversial FRAM study.
|
|
|
August 16, 2006
|
IAC: Tibotec VP Discusses Latest On Prezista
AIDSmeds Founder Peter Staley interviewed Dr. Alan Tennenberg, Tibotec's VP of Clinical Affairs, regarding the latest clinical data on Prezista, the newly approved protease inhibitor.
|
|
|
IAC: Nutritional Boost CD4 Counts
Longtime nutrition advocate Jon Kaiser, MD, and his colleagues presented data at the XVI International AIDS Conference regarding the effects of micronutrient supplementation on CD4 cell counts (T cell counts).
|
|
|
IAC: Meds Improve Growth and Body Composition
New data reported at the XVI International AIDS Conference (IAC) in Toronto indicates that HIV treatment dramatically improves growth and body composition in HIV-positive children.
|
|
|
IAC: AIDS Focus Shifts to Prevention
Circumcision, microbicides and drugs all offer promising new possibilities for battling the AIDS pandemic, but it will not be easy to roll out this arsenal of prevention methods, according to a report by the Global HIV Prevention Working Group, presented to the International Conference on AIDS.
|
|
|
August 15, 2006
|
IAC: Encouraging Data on Etravirine (TMC-125)
Researchers at the XVI International AIDS Conference in Toronto have reported 48-week results from a phase II clinical trial of etravirine (TMC-125), Tibotec's experimental non-nucleoside reverse transcriptase inhibitor (NNRTI).
|
|
|
IAC: 48-Week Prezista POWER Results Presented
Additional results from two ongoing clinical trials of Prezista (darunavir), Tibotec, Inc.’s protease inhibitor approved by the U.S. Food and Drug Administration (FDA) in June, suggest that the drug offers prolonged treatment effects for HIV-positive people with limited treatment options.
|
|
|
Updated Treatment Guidelines for Adult HIV
The International AIDS Society-USA Panel has released guidelines updating its treatment recommendations for adult HIV infection, according to a report in the August 16th issue of the Journal of the American Medical Association.
|
|
|
August 14, 2006
|
IAC: Serostim As Immune-Based Therapy?
Recombinant human growth hormone (Serostim®), best known as an approved anti-wasting treatment and an experimental anti-lipodystrophy agent, has entered an unexpected area of HIV treatment research: immune-based therapies.
|
|
|
IAC: Four Drugs Vs. Three
Is a four-drug regimen any more effective than the current three-drug standard? Not according to a recent study reviewed at the XVI International AIDS Conference in Toronto.
|
|
|
August 11, 2006
|
HIV Impairs CD8 Responsiveness
Patients co-infected with hepatitis C virus (HCV) and HIV show a reduced responsiveness of CD8 T cells to stimulation by CD28 cells compared with patients infected with HCV alone.
|
|
|
| August 09, 2006
|
August 08, 2006
|
Dosing Questions May Slow TNX-355 Development
Tanox, a Houston-based pharmaceutical company, has been instructed by the U.S. Food and Drug Administration (FDA) to complete another round of preliminary clinical trials of its entry inhibitor TNX-355 before moving the drug into advanced studies.
|
|
|
| August 04, 2006
|
August 01, 2006
|
New Genetic Test Ready for Prime Time?
Independent Forensics, an Illinois-based company specializing in paternity testing and DNA evidence used in criminal investigations, has begun marketing a genetic assay intended for HIV-positive people.
|
|
|
HIV Hides from Treatment in the Gut
A University of California research team has discovered that HIV is able to survive the antiviral effects of treatment by hiding out in the mucosal tissues of the intestine.
|
|
|
|
|
Have news about HIV? Send press releases, news tips and other announcements to news@poz.com. |
|
  November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006
|
